Immunogenicity of recombinant adeno-associated virus (AAV) vectors for gene transfer
Recombinant adeno-associated viruses (AAVs) have emerged as promising gene delivery
vehicles resulting in three US Food and Drug Administration (FDA) and one European …
vehicles resulting in three US Food and Drug Administration (FDA) and one European …
CAR-T regulatory (CAR-Treg) cells: engineering and applications
M Arjomandnejad, AL Kopec, AM Keeler - Biomedicines, 2022 - mdpi.com
Regulatory T cells are critical for maintaining immune tolerance. Recent studies have
confirmed their therapeutic suppressive potential to modulate immune responses in organ …
confirmed their therapeutic suppressive potential to modulate immune responses in organ …
[HTML][HTML] A versatile toolkit for overcoming AAV immunity
X Li, X Wei, J Lin, L Ou - Frontiers in Immunology, 2022 - frontiersin.org
Recombinant adeno-associated virus (AAV) is a promising delivery vehicle for in vivo gene
therapy and has been widely used in> 200 clinical trials globally. There are already several …
therapy and has been widely used in> 200 clinical trials globally. There are already several …
Suppression of heterotopic ossification in fibrodysplasia ossificans progressiva using AAV gene delivery
YS Yang, JM Kim, J Xie, S Chaugule, C Lin… - Nature …, 2022 - nature.com
Heterotopic ossification is the most disabling feature of fibrodysplasia ossificans
progressiva, an ultra-rare genetic disorder for which there is currently no prevention or …
progressiva, an ultra-rare genetic disorder for which there is currently no prevention or …
New cell sources for CAR-based immunotherapy
M Mazinani, F Rahbarizadeh - Biomarker Research, 2023 - Springer
Chimeric antigen receptor (CAR) T cell therapy, in which a patient's own T lymphocytes are
engineered to recognize and kill cancer cells, has achieved striking success in some …
engineered to recognize and kill cancer cells, has achieved striking success in some …
A single surface-exposed amino acid determines differential neutralization of AAV1 and AAV6 by human alpha-defensins
Adeno-associated viruses (AAVs) are being developed as gene therapy vectors due to their
low pathogenicity and tissue tropism properties. However, the efficacy of these vectors is …
low pathogenicity and tissue tropism properties. However, the efficacy of these vectors is …
Evaluation of cellular immune response to adeno-associated virus-based gene therapy
B Gorovits, M Azadeh, G Buchlis, M Fiscella… - The AAPS journal, 2023 - Springer
The number of approved or investigational late phase viral vector gene therapies (GTx) has
been rapidly growing. The adeno-associated virus vector (AAV) technology continues to be …
been rapidly growing. The adeno-associated virus vector (AAV) technology continues to be …
Gene therapy for alpha-1 antitrypsin deficiency: an update
D Pires Ferreira, AM Gruntman… - Expert Opinion on …, 2023 - Taylor & Francis
Introduction Altering the human genetic code has been explored since the early 1990s as a
definitive answer for the treatment of monogenic and acquired diseases which do not …
definitive answer for the treatment of monogenic and acquired diseases which do not …
Understanding and tackling immune responses to adeno-associated viral vectors
H Costa-Verdera, C Unzu, E Valeri, S Adriouch… - Human Gene …, 2023 - liebertpub.com
As the clinical experience in adeno-associated viral (AAV) vector-based gene therapies is
expanding, the necessity to better understand and control the host immune responses is …
expanding, the necessity to better understand and control the host immune responses is …
CAR-Treg cell therapies and their future potential in treating ocular autoimmune conditions
AR Abraham, P Maghsoudlou, DA Copland… - Frontiers in …, 2023 - frontiersin.org
Ophthalmic autoimmune and autoinflammatory conditions cause significant visual morbidity
and require complex medical treatment complicated by significant side effects and lack of …
and require complex medical treatment complicated by significant side effects and lack of …